Conventional Sacroiliac Joint Injection Versus Pulsed Radiofrequency in SIJ Pain

July 12, 2026 updated by: Walaa Youssef Elsabeeny, National Cancer Institute, Egypt

Unlocking Sacroiliac Joint Pain: A Comparative Study of Pulsed Radiofrequency and Conventional Technique

Therapeutic options for SIJ pain include intra-articular corticosteroid injections, which provide symptomatic relief but typically require repeated administration due to variable and short-lived efficacy.

More recently, pulsed radiofrequency (PRF) has been investigated for joint pain management through intra-articular electrode placement and stimulation. However, its effectiveness in treating SIJ pain remains insufficiently studied and warrants further exploration.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion criteria

  • Sacroiliac Joint (SIJ) Pain
  • Diagnostic Block Response: Demonstrated a pain reduction of at least 50% following a diagnostic intra- articular SIJ block.
  • Failure of Medical Management
  • Chronic Pain Duration: Presence of chronic pain for a minimum duration of 6 months.
  • Pain Intensity: A pain intensity score greater than 5 on a 10-point Numeric Rating Scale (NRS), where 0 represents no pain and 10 represents the worst imaginable pain.
  • Age: Aged between 18 and 65 years.
  • Body Mass Index (BMI): A BMI within the range of 20 kg/m² to 35 kg/m².

Exclusion Criteria:

  • Patient refusal.
  • Local infection at the puncture site.
  • Coagulopathies with platelets count below 50,000 or an INR>1.6.
  • Unstable cardiovascular disease and Poor general condition and severe respiratory distress.
  • History of psychiatric and cognitive disorders or opioid addiction.
  • Patients are allergic to medication used.
  • Previous surgery to the affected site.
  • Rheumatological disease such as rheumatoid arthtritis or ankylsoing spondyolitis.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Conventional injection
Particulate steroid injection in SIJ
Procedure: Conventional injection
Sacroiliac joint (SIJ) steroid injection
Experimental: Pulsed radiofrequency of SIJ
Procedure: Pulsed radiofrequency (PRF)
PRF of Sacroiliac Joint (SIJ)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Numeric rating score (NRs) reduction
Time Frame: 1 month
Numeric rating score (NRs) reduction of pain scores after 1 month
1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

National Cancer Institute, Egypt

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

July 12, 2026

Primary Completion (Estimated)

August 1, 2027

Study Completion (Estimated)

September 1, 2027

Study Registration Dates

First Submitted

July 12, 2026

First Submitted That Met QC Criteria

July 12, 2026

First Posted (Actual)

July 16, 2026

Study Record Updates

Last Update Posted (Actual)

July 16, 2026

Last Update Submitted That Met QC Criteria

July 12, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AP2603-501-165-208

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe